NCT06769425 - HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

May 7, 2026

Study Completion Date

August 31, 2026

Conditions

Recurrent Ovarian CancerHER2-negativeAdvanced Breast CancerTNBCAdvanced Prostate CancerAdvanced Gastric Cancer

Interventions

DRUG

HS-10502 + NHA

DRUG

HS-10502 + HS-20093

DRUG

HS-10502+ Apatinib

DRUG

HS-10502 + HS-20089

DRUG

HS-10502 + Platinum + Bevacizumab

DRUG

HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan

DRUG

HS-10502 + Bevacizumab

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai